Dr Walewska's ASH 2023 Highlights 

Speaking during the ASH 2023 congress, Dr Renata Walewska (University Hospitals Dorset) expands on fixed-duration venetoclax therapy and treatment sequencing in CLL.

Fitness for VEN+O

Dr Nicolas Martinez-Calle (Nottingham University Hospital) describes how a pooled analysis of data from CLL-13 and CLL-14, presented at ASH 2023, highlights that VEN+O may offer a front-line option for CLL patients across different age and fitness groups.¹

Dr Patten's ASH 2023 Highlights

Dr Piers Patten (King's College London) describes how long-term follow-up data from CLL-13, a front-line study of VEN+O in CLL, is helping inform treatment decision-making.²

MURANO – Insights on treatment sequencing & VENCLYXTO retreatment

Insights from Dr Piers Patten (King's College London), speaking during ASH 2023, following data updates from the MURANO study relating to treatment sequencing.³

Fitness for VEN+O as a first-line therapy

Insights from a pooled analysis of CLL-13 and CLL-14 studies underscores the place for VEN+O in first-line management of CLL.¹

Evidence and arguments for fixed treatment duration in CLL

Dr Toby Eyre (Oxford) navigates the current evidence to provide a succinct summary and rationale for fixed-duration treatment approaches to CLL treatment.

CLL-13 overview

Dr Toby Eyre (Oxford) provides a bite-sized summary of the 3-year data from CLL-13 and what the findings mean for fit, previously untreated patients.⁴

Venetoclax CLL14 data – An overview of 6-year follow-up

Watch Dr Toby Eyre (Oxford) as he summarises the latest data read-outs from CLL-14, 5-years after the end of treatment in older, previously untreated patients with comorbidities.^5,6

Update on MURANO

In this video, Dr Toby Eyre (Oxford) discusses the final 7-year follow-up data from the MURANO study, a global, phase III open-label, randomised study of patients with R/R CLL being treated with VEN+R compared with bendamustine plus rituximab.⁷

ACP-led Ambulatory Service – Sharing our experience in Chesterfield

Haematology ACP Matthew Smith describes how he rose to the challenge to produce and lead an ambulatory service for patients with AML without an increase in funding or allocation of clinical space.

The CNS/Pharmacist Clinic in Cardiff 

Discover the value of incorporating advanced practitioners into CLL and low-grade lymphoma consultant-led clinics from the perspective of Asjad Yousif, an Advanced Clinical Pharmacist, and Charlotte Bloodsworth, an Advanced Nurse Practitioner.

Experience with developing successful business cases

Glean valuable insight from haematologist Professor Adrian Bloor as he shares his 14 rules for developing business cases that persuade.

VENCLYXTO initiation & off-boarding in CLL

Watch specialist nurse Christina Kirby describe her experience and insights on on-boarding and off-boarding patients prescribed VEN+O at Basingstoke Hospital.

CLL – On-boarding patients with VENCLYXTO

Insights from Dr Nick Martinez-Calle (Nottingham) on treatment initiation for CLL patients starting VENCLYXTO-based therapy.

Holistic management in CLL

Dr Samir Agrawal, Senior Lecturer at the Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust, advocates patient-empowering, holistic treatment in CLL patients.

Dr Nimish Shah and Sharon March discuss how they manage first-line patients on VEN+O at Norfolk and Norwich University Hospital.

Front line CLL – the impact of genetic markers on treatment selection

Dr Othman Al-Sawaf of the German CLL Study Group provides insights on how genetic markers may impact the selection of front-line treatments for patients with CLL.

Evidence and arguments for fixed duration treatment in CLL

Dr Toby Eyre (Oxford) navigates the current evidence to produce a succinct summary and rationale for fixed duration treatment approaches to CLL treatment.

CLL-decision-making in the relapsed/refractory setting

View an expert, case-based panel discussion, led by Dr Toby Eyre (Oxford), on the available evidence base from RCTs and real-world cohorts,  for treatment of patients relapsing after CIT, after prior BCRi therapy or after venetoclax-based therapy. Featuring Dr Toby Eyre, Dr Dima El-Sharkawi, Dr Talha Munir, Dr Piers Patten & Dr Stella Williams.

An overview of the evolving front-line treatment landscape in CLL

Watch Dr Talha Munir (Leeds) present a succinct overview of the data supporting front-line treatment choices in CLL, including insights on fixed-duration and continuous treatment regimens, and the data regarding treatment choice according to TP53 and IGHV mutational status.